Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Assets: 2019-2025

Historic Return on Assets for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to -0.73%.

  • BridgeBio Pharma's Return on Assets fell 17.00% to -0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.73%, marking a year-over-year decrease of 17.00%. This contributed to the annual value of -0.74% for FY2024, which is 38.00% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Return on Assets of -0.73% as of Q3 2025, which was up 2.98% from -0.76% recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Return on Assets peaked at -0.51% during Q2 2021, and registered a low of -1.12% during Q4 2023.
  • Its 3-year average for Return on Assets is -0.80%, with a median of -0.76% in 2025.
  • Per our database at Business Quant, BridgeBio Pharma's Return on Assets declined by 30bps in 2023 and then skyrocketed by 54bps in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Return on Assets stood at -0.69% in 2021, then dropped by 17bps to -0.87% in 2022, then dropped by 25bps to -1.12% in 2023, then surged by 50bps to -0.61% in 2024, then declined by 17bps to -0.73% in 2025.
  • Its Return on Assets was -0.73% in Q3 2025, compared to -0.76% in Q2 2025 and -0.68% in Q1 2025.